Fetal Alcohol Syndrome
18
3
3
12
Key Insights
Highlights
Success Rate
92% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
5.6%
1 terminated out of 18 trials
92.3%
+5.8% vs benchmark
11%
2 trials in Phase 3/4
17%
2 of 12 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 12 completed trials
Clinical Trials (18)
In Utero Alcoholic Exposure: PlGF, Biomarker of Fetal Brain Lesions
Scaling Up: A Multi-Site Trial of e-SBI for Alcohol Use in Pregnancy
RCT of Prenatal Choline Supplementation During Pregnancy to Mitigate Adverse Effects of Prenatal Alcohol Exposure
The Oklahoma Parent-Child Assistance Program
Multisensorial Analysis of Human Activity for Diagnosis and Early Detection of Functional Limitations
Neighborhood Alcohol & HIV Prevention in South African Townships (Philani)
Prenatal Alcohol Biomarker Study in Uruguay
Open-Label Study of the Long Term Tolerability and Safety of Atomoxetine in Children With FASD and ADD/ADHD
Assess the Effectiveness of Atomoxetine in Children With Fetal Alcohol Syndrome and ADD/ADHD
Postnatal Choline Supplementation in Children With Prenatal Alcohol Exposure
Expansion to Interdisciplinary HIV Prevention in Women
Healthy Moms Alcohol Intervention
Choline Supplementation in Children With Fetal Alcohol Spectrum Disorders
Evaluating the Efficacy of a Video Based Intervention to Educate Teen Moms About Fetal Alcohol Syndrome (FAS)
Neurocognitive Habilitation for Children With Fetal Alcohol Syndrome (FAS)/Alcohol-Related Neurodevelopmental Disorder (ARND)
Fetal Alcohol Damage Prevention Study
Fetal Alcohol Syndrome: Socio-Cognitive Habilitation
Fetal Alcohol Syndrome/ARND Research Consortion